$RVMD SEC Filing Alert & Real-Time AI Stock Impact Analysis

$RVMD triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: Revolution Medicines Reports Q3 2026: RASONQUE Launches with $198M Revenue, Net Loss Widens to $407.5M. Key points: - RASONQUE (daraxonrasib) generated $198 million in net product revenue during a partial launch quarter following FDA approval - Net loss widened to $407.5 million (-$1.90/share) from $305.2 million in Q3 2025 - Full-year 2026 GAAP operating expense guidance reiterated at $2.1B-$2.2B

After the SEC 8-K for $RVMD, observed market reaction: T0 price $199.70. Past moves do not guarantee future results.

Stock Catalyst AI pushes real-time SEC 8-K alerts for $RVMD via Telegram and the VIP Web Terminal from €10/month.